| 1. |
|
|
| 2. |
|
|
| 3. |
|
|
| 4. |
- Mezei, J. Z., et al.
(författare)
-
Mutual neutralization in low-energy H(+) + F(-) collisions
- 2011
-
Ingår i: Physical Review A. Atomic, Molecular, and Optical Physics. - 1050-2947 .- 1094-1622. ; 84:1, s. 012703-
-
Tidskriftsartikel (refereegranskat)abstract
- The cross section for mutual neutralization in collisions between H(+) and F(-) ions at low energies ( E <= 10 eV) is calculated using a molecular close-coupling approach. Two different representations of the quasidiabatic potentials and couplings of HF are used. The effect of autoionization on the cross section is investigated. The coupled Schrodinger equation for the nuclear motion is solved using a numerical integration of the corresponding matrix Riccati equation and the cross section for mutual neutralization is computed from the asymptotic value of the logarithmic derivative of the radial wave function. The magnitude of the cross section for mutual neutralization in this reaction is small compared to other systems. This can be understood by the lack of avoided crossings at large internuclear distances. Resonant structures are found in the cross section and these are assigned with dominant angular momentum quantum number. The cross section for mutual neutralization in collisions of D(+) and F(-) ions is also calculated.
|
|
| 5. |
- Santoro, V., et al.
(författare)
-
DEVELOPMENT OF A HIGH INTENSITY NEUTRON SOURCE AT THE EUROPEAN SPALLATION SOURCE : THE HIGHNESS PROJECT
- 2022
-
Ingår i: Proceedings of the 14th International Topical Meeting on Nuclear Applications of Accelerators, AccApp 2021, Embedded with the 2021 ANS Winter Meeting. - 9780894487842 ; , s. 11-20
-
Konferensbidrag (refereegranskat)abstract
- The European Spallation Source (ESS), presently under construction in Lund, Sweden, is a multidisciplinary international laboratory that will operate the world’s most powerful pulsed neutron source. Supported by a 3M Euro Research and Innovation Action within the EU Horizon 2020 program, a design study (HighNESS) is now underway to develop a second neutron source below the spallation target. Compared to the first source, located above the spallation target and designed for high cold and thermal brightness, the new source will provide higher intensity, and a shift to longer wavelengths in the spectral regions of cold (2-20 Å), very cold (VCN, 10-120 Å), and ultra cold (UCN, > 500 Å) neutrons. The core of the second source will consist of a large liquid deuterium moderator to deliver a high flux of cold neutrons and to serve secondary VCN and UCN sources, for which different options are under study. The features of these new sources will boost several areas of condensed matter research and will provide unique opportunities in fundamental physics. Part of the HighNESS project is also dedicated to the development of future instruments that will make use of the new source and will complement the initial suite of instruments in construction at ESS. The HighNESS project started in October 2020. In this paper, the ongoing developments and the results obtained in the first year are described.
|
|
| 6. |
- Santos-Valente, E, et al.
(författare)
-
Biologicals in childhood severe asthma: the European PERMEABLE survey on the status quo
- 2021
-
Ingår i: ERJ open research. - : European Respiratory Society (ERS). - 2312-0541. ; 7:3
-
Tidskriftsartikel (refereegranskat)abstract
- Severe asthma is a rare disease in children, for which three biologicals, anti-immunoglobulin E, anti-interleukin-5 and anti-IL4RA antibodies, are available in European countries. While global guidelines exist on who should receive biologicals, knowledge is lacking on how those guidelines are implemented in real life and which unmet needs exist in the field. In this survey, we aimed to investigate the status quo and identify open questions in biological therapy of childhood asthma across Europe.MethodsStructured interviews regarding experience with biologicals, regulations on access to the different treatment options, drug selection, therapy success and discontinuation of therapy were performed. Content analysis was used to analyse data.ResultsWe interviewed 37 experts from 25 European countries and Turkey and found a considerable range in the number of children treated with biologicals per centre. All participating countries provide public access to at least one biological. Most countries allow different medical disciplines to prescribe biologicals to children with asthma, and only a few restrict therapy to specialised centres. We observed significant variation in the time point at which treatment success is assessed, in therapy duration and in the success rate of discontinuation. Most participating centres intend to apply a personalised medicine approach in the future to match patients a priori to available biologicals.ConclusionSubstantial differences exist in the management of childhood severe asthma across Europe, and the need for further studies on biomarkers supporting selection of biologicals, on criteria to assess therapy response and on how/when to end therapy in stable patients is evident.
|
|
